Zobrazeno 1 - 10
of 186
pro vyhledávání: '"William V, Williams"'
Autor:
Charles L. Wiseman, Jarrod P. Holmes, Carmen Calfa, Shaker R. Dakhil, Saveri Bhattacharya, George E. Peoples, Markus D. Lacher, Miguel Lopez-Lago, Alex Kharazi, Giuseppe Del Priore, Mingjin Chang, Daniel L. Adams, William V. Williams
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
This Phase I/IIa open-label, single-arm clinical trial addressing advanced, refractory, metastatic breast cancer was conducted at six medical centers in the United States. We repeated inoculations with irradiated SV-BR-1-GM, a breast cancer cell line
Externí odkaz:
https://doaj.org/article/67922cae6ff54870900ebf2a5b42091c
Autor:
Sagarika Pachhal, Miguel A Lopez-Lago, Vikas Bhardwaj, Xiaoyi Zheng, Pravin Kesarwani, Patience Cournoo, Renee Cortez, Charles L Wiseman, William V Williams
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f8e8cfe7d00e4d829a031c4ce6652412
Autor:
Markus D. Lacher, Charles L. Wiseman, Alexander Kharazi, Vivekananda G. Sunkari, Jacqueline L. Galeas, Vito Dozio, Hind Hashwah, Eva Macúchová, William V. Williams
Publikováno v:
Recent Patents on Anti-Cancer Drug Discovery. 18:224-240
Background: SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by s
Publikováno v:
The Linacre Quarterly. 89:368-370
Autor:
Markus D. Lacher, Gerhard Bauer, Brian Fury, Sanne Graeve, Emily L. Fledderman, Tye D. Petrie, Dane P. Coleal-Bergum, Tia Hackett, Nicholas H. Perotti, Ying Y. Kong, William W. Kwok, Joseph P. Wagner, Charles L. Wiseman, William V. Williams
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Targeted cancer immunotherapy with irradiated, granulocyte–macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients. It is generally assumed that
Externí odkaz:
https://doaj.org/article/be434467daf447fe95c59f3f971bd772
Autor:
Kathleen M. Raviele, Lester Ruppersberger, Michael Gaskins, Hanna Klaus, Laura Haynes, William V. Williams, Michael D Manhart, Joel Brind, Angela Lanfranchi, Elvis I Šeman, Gerard Migeon
Publikováno v:
Linacre Q
To investigate the sociological, environmental, and economic impact of hormonally active contraceptives, a series of comprehensive literature surveys were employed. Sociological effects are discussed including abortion, exploitation of women, a weake
Autor:
Saranya Chumsri, Minal Barve, Chaitali Nangia, Bonnie L. Guerin, Jarrod Holmes, Karim Mohammed, John Knecht, Shaker Dakhil, William V. Williams, Charles Wiseman, Mingjin Chang, Miguel Lopez-Lago, John G. Knecht, Kendrith Rowland, Ralph V. Boccia, Giuseppe Del Priore, Carmen Calfa
Publikováno v:
Cancer Research. 83:CT143-CT143
Background: Bria-IMT (SV-BR-1-GM) is an off-the-shelf whole tumor cell therapeutic vaccine engineered to express class I & class II HLAs, secrete GM-CSF, and function as antigen-presenting cells; with subsequent enhancements improving in-vitro charac
Autor:
Dimpal M. Kasabwala, Massimo Cristofanilli, R. Katherine Alpaugh, Saranya Chumsri, Carolina Reduzzi, Cha-Mei Tang, Rena G. Lapidus, Giuseppe Del Priore, William V. Williams, Daniel L. Adams
Publikováno v:
Cancer Research. 83:304-304
Background: Micronuclei (MN) are a result of biological DNA repair mechanisms which form due to internal chromosomal aberrations indicating sub-clonal cancer populations with higher cell survivability and drug therapy resistance. MN are often observe
Autor:
Jarrod P. Holmes, Shaker R. Dakhil, Vivek G Sunkari, Jason Lukas, Markus D. Lacher, William V. Williams, Elizabeth Tan-Chiu, Charles L. Wiseman, Carmen Calfa, George E. Peoples, Saveri Bhattacharya
Publikováno v:
Cancer Research. 81:PS17-20
Background: SV-BR-1-GM is a GM-CSF transfected breast cancer cell line, exceptional for having antigen-presenting capability and expressing both HLA I and II. The parent cell line, SV-BR-1, was derived from a patient with grade II (moderately differe
Autor:
Markus D. Lacher, Vivek G Sunkari, Shaker R. Dakhil, Charles L. Wiseman, Diane DaSilva, Saveri Bhattacharya, Carmen Calfa, Ajay Kundra, George E. Peoples, Jarrod P. Holmes, William V. Williams, Daniel L. Adams
Publikováno v:
Cancer Research. 80:P3-09
Background: SV-BR-1-GM is a GM-CSF transfected breast cancer cell line, exceptional for having antigen-presenting capability expressing both HLA I and II. We report clinical efficacy, safety, and immunologic correlates of response from our initial Ph